Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations
Authors:
- Angela CapolupoACAngela Capolupo
- Sofia PetrocchiSPSofia Petrocchi
- Maura MelchiorreMMMaura Melchiorre
- Kim JonasKJKim Jonas
- Thomas D’hoogheTDThomas D’hooghe
- Aylin HanyalogluAHAylin Hanyaloglu
- Sesh SunkaraSSSesh Sunkara
- Angelo PalmeseAPAngelo Palmese
- Beste OzgumusBOBeste Ozgumus
- Angela AmoresanoAAAngela Amoresano
- Gabriella AngiuoniGAGabriella Angiuoni
- Susana MontenegroSMSusana Montenegro
Open Access
- 29 August 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (17) , 9405
Abstract
Highly purified human menopausal gonadotropin (HP-hMG [Menopur®, Ferring Pharmaceuticals, Saint-Prex, Switzerland]) contains a 1:1 ratio of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This analysis aimed to assess gonadotropin (FSH, LH and hCG) abundance in HP-hMG and clarify the source of hCG by assessing the presence of sulfated glycans, which are diagnostic for pituitary hCG forms due to their distinct glycosylation patterns. Additionally, the purity of each sample, their specific components, and their oxidation levels were assessed. HP-hMG samples (three of Menopur® and two of Menogon® Ferring Pharmaceuticals, Saint-Prex, Switzerland) were included in the current analyses. Brevactid® (urinary hCG; Ferring Pharmaceuticals, Saint-Prex, Switzerland) and Ovidrel® (recombinant hCG; Merck KGaA, Darmstadt, Germany) were used as control samples. Glycopeptide mapping and analysis of impurities were carried out by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Oxidation was assessed through reducing peptide mapping using LC-MS/MS. The FSH and LH in the HP-hMG samples showed sulfated glycans, while no signals of sulfated glycopeptides were detected on any site of the beta subunit of hCG. HP-hMG test samples presented the same hCG glycan distribution as the control sample (placental hCG, Brevactid®) extracted from the urine of pregnant women, suggesting a non-pituitary source of hCG. Protein impurities were estimated to constitute approximately 20–30% of the entire HP-hMG protein content in the test samples. More than 200 non-gonadotropin proteins were identified in the HP-hMG test samples, of which several were involved in embryonic development or pregnancy. The alpha subunit of the tested samples was strongly oxidized, with a relative abundance of 20% of the total gonadotropin content. Without taking into account all the protein impurities, the beta subunit of LH was detected only in traces (0.9–1.2%) in all tested HP-HMG samples, confirming the data obtained by intact molecule analysis, while high levels of beta hCG (18–47%) were observed. Advanced molecular analysis of HP-hMG indicates a primarily placental origin of hCG, as evidenced by the absence of hCG sulfated glycans and the predominance of placental non-sulfated hCG in LH activity. The analysis revealed 20–30% of protein impurities and a significant presence of oxidized forms in the HP-hMG samples. These findings are critical for understanding the quality, safety, and clinical profile of HP-hMG.Keywords
Funding Information
- Merck KGaA (Darmstadt, Germany)
This publication has 33 references indexed in Scilit:
- Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trialReproductive BioMedicine Online, 2019
- Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trialFertility and Sterility, 2017
- Luteinizing hormone and human chorionic gonadotropin: Origins of differenceMolecular and Cellular Endocrinology, 2014
- A pilot study on potency determination of human follicle-stimulating hormone: A comparison between reversed-phase high-performance liquid chromatography method and the in vivo bioassayJournal of Pharmaceutical and Biomedical Analysis, 2011
- Analytical identification of additional impurities in urinary-derived gonadotrophinsReproductive BioMedicine Online, 2009
- Recombinant HCG for triggering ovulation increases the rate of mature oocytes in women treated for ICSIJournal of Assisted Reproduction and Genetics, 2008
- Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin α)Reproductive BioMedicine Online, 2006
- Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trialFertility and Sterility, 2002
- Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassayFertility and Sterility, 1998
- Metabolism of hCG and hLH to multiple urinary formsMolecular and Cellular Endocrinology, 1996